Education
About Us
Working with TipRanks
Follow Us
Cingulate, Inc. (CING)
:CING
CING Stock Chart & Stats
$3.70
-$0.31(-6.60%)
At close: 4:00 PM EST
$3.70
-$0.31(-6.60%)
Day’s Range― - ―
52-Week Range$3.02 - $6.01
Previous CloseN/A
Volume136.88K
Average Volume (3M)190.99K
Market Cap
$20.74M
Enterprise Value$15.55M
Total Cash (Recent Filing)$8.90M
Total Debt (Recent Filing)$6.58M
Price to Earnings (P/E)―
Beta5.12
Next Earnings
Nov 17, 2025EPS Estimate
-0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding5,606,039
10 Day Avg. Volume270,731
30 Day Avg. Volume190,985
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)2.52
Price to Sales (P/S)0.00
P/FCF Ratio-1.01
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda-0.89
Forecast
1Y Price Target
$29.00Price Target Upside683.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Market OpportunityConsidering the ongoing stimulant shortages, especially for generic stimulant products, and that CTx-1301 only requires one daily dose, the commercial opportunity for Cingulate is significant.
PartnershipsCingulate's partnership with Indegene, a company with over 20 years of experience, provides extensive services and AI-driven analytics to support a successful product launch.
Regulatory ProgressThe FDA accepted Cingulate's NDA application for CTx-1301, indicating a significant step forward for the company's ADHD treatment.
Bears Say
Investor ConcernsShares are trading down due to investor concerns around regulatory risks, including potential concerns about the Phase 3 data, commercial risks, or potential delays by the FDA.
Cingulate Inc News
CING FAQ
What was Cingulate, Inc.’s price range in the past 12 months?
Cingulate, Inc. lowest stock price was $3.02 and its highest was $6.01 in the past 12 months.
What is Cingulate, Inc.’s market cap?
Cingulate, Inc.’s market cap is $20.74M.
When is Cingulate, Inc.’s upcoming earnings report date?
Cingulate, Inc.’s upcoming earnings report date is Nov 17, 2025 which is in 28 days.
How were Cingulate, Inc.’s earnings last quarter?
Cingulate, Inc. released its earnings results on Aug 19, 2025. The company reported -$1.09 earnings per share for the quarter, missing the consensus estimate of -$0.915 by -$0.175.
Is Cingulate, Inc. overvalued?
According to Wall Street analysts Cingulate, Inc.’s price is currently Undervalued.
Does Cingulate, Inc. pay dividends?
Cingulate, Inc. does not currently pay dividends.
What is Cingulate, Inc.’s EPS estimate?
Cingulate, Inc.’s EPS estimate is -0.88.
How many shares outstanding does Cingulate, Inc. have?
Cingulate, Inc. has 5,606,039 shares outstanding.
What happened to Cingulate, Inc.’s price movement after its last earnings report?
Cingulate, Inc. reported an EPS of -$1.09 in its last earnings report, missing expectations of -$0.915. Following the earnings report the stock price went down -9.615%.
Which hedge fund is a major shareholder of Cingulate, Inc.?
Among the largest hedge funds holding Cingulate, Inc.’s share is GoalVest Advisory LLC. It holds Cingulate, Inc.’s shares valued at 0.
Company Description
Cingulate, Inc.
Cingulate Inc. is a biopharmaceutical company focused on the development, manufacturing, and commercialization of innovative therapies for the treatment of central nervous system disorders. Operating primarily in the healthcare and pharmaceutical sectors, the company is dedicated to addressing unmet medical needs through its portfolio of proprietary drug candidates, with a particular emphasis on attention deficit/hyperactivity disorder (ADHD) and anxiety disorders.
CING Stock 12 Month Forecast
Average Price Target
$29.00
▲(683.78% Upside)
Technical Analysis
Bio Green Med Solution
―
NanoViricides
―
Enlivex
―
FibroBiologics, Inc.
―
Boundless Bio Inc.
―
Ownership Overview
36.19% Insiders
1.07% Mutual Funds
0.42% Other Institutional Investors
61.60% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---